货号:A1006406 同义名: PF-04971729 L-pyroglutamic acid;MK-8835 L-pyroglutamic acid
Ertugliflozin L-pyroglutamic acid (PF-04971729 L-pyroglutamic acid) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2[1]. A drug for the treatment of type 2 diabetes mellitus[2].
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
产品名称 | SGLT1 ↓ ↑ | SGLT2 ↓ ↑ | 其他靶点 | 纯度 | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Phloretin | ✔ | 98% | |||||||||||||||||
Canagliflozin |
+++
hSGLT2, IC50: 3.7 nM mSGLT2, IC50: 2 nM |
95% | |||||||||||||||||
Empagliflozin |
++
SGLT2, IC50: 3.1 nM |
98% | |||||||||||||||||
Dapagliflozin |
++++
hSGLT2, EC50: 1.1 nM |
97% | |||||||||||||||||
Tofogliflozin (hydrate) |
+++
hSGLT2, IC50: 2.9 nM |
99%+ | |||||||||||||||||
Sotagliflozin |
+
SGLT1, IC50: 36 nM |
++++
SGLT2, IC50: 1.8 nM |
98% | ||||||||||||||||
Ipragliflozin |
++
hSGLT2, IC50: 7.4 nM |
98% | |||||||||||||||||
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 |
描述 | Ertugliflozin L-pyroglutamic acid (PF-04971729 L-pyroglutamic acid) is a potent, selective, and orally administered inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), exhibiting an IC50 of 0.877 nM against h-SGLT2[1]. |
体内研究 | Ertugliflozin L-pyroglutamic acid induces a dose-dependent increase in glucose excretion in the urine following its oral delivery to rats, demonstrating its effectiveness in promoting glucosuria[3]. |
体外研究 | In vitro, Ertugliflozin L-pyroglutamic acid (PF-04971729 L-pyroglutamic acid) demonstrates >2000-fold selectivity for SGLT2 inhibition (relative to SGLT1) [3]. |
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
1.77mL 0.35mL 0.18mL |
8.83mL 1.77mL 0.88mL |
17.67mL 3.53mL 1.77mL |
CAS号 | 1210344-83-4 |
分子式 | C27H32ClNO10 |
分子量 | 565.997 |
别名 | PF-04971729 L-pyroglutamic acid;MK-8835 L-pyroglutamic acid |
运输 | 蓝冰 |
存储条件 |
液体 -20°C:3-6个月-80°C:12个月 粉末 Inert atmosphere,2-8°C |
溶解度 |
DMSO: 120 mg/mL(212.02 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO H2O: 5 mg/mL(8.83 mM),配合低频超声,并水浴加热至45℃助溶 |
动物实验配方 |